Is there room for immunomodulators in ulcerative colitis?

Area of Science:

• Gastroenterology
• Immunology
• Pharmacology

Background:

• Ulcerative colitis (UC) management has evolved with new biologic and small molecule therapies.
• Traditional immunomodulators (IMMs) like thiopurines and methotrexate roles are being re-evaluated.
• Aminosalicylates are standard for mild-to-moderate UC; IMMs' place in moderate-to-severe UC is less clear.

Purpose of the Study:

• To review the mechanism of action of thiopurines and methotrexate.
• To identify clinical parameters for IMM use in UC.
• To appraise the evidence for IMM efficacy and safety in UC, including combination therapies.

Main Methods:

• Review of prospective, controlled data on thiopurines and methotrexate in UC.
• Analysis of IMMs as monotherapy and in combination with other UC treatments.
• Evaluation of clinical parameters guiding IMM selection.

Main Results:

• Emerging data suggest no significant benefit of IMMs over placebo in some UC patient populations.
• Concerns exist regarding the long-term safety profile of IMM exposure.
• Evidence supports a more restricted role for IMMs in UC treatment algorithms.

Conclusions:

• The role of thiopurines or methotrexate in UC should be limited.
• Consider IMMs for milder UC cases unresponsive to aminosalicylates alone.
• Restrict IMMs to combination therapy with TNF antagonists for moderate-to-severe UC patients failing other treatments.